Search results for: England
Filter search results
Chronic Diseases and the Stock of Health: Quantification Using EQ-5D-5L
15 October 2019
…An EQ-5D-5L value set for England. Health Economics, 27(1), pp.7–22. DOI. RePEc. Feng, Y., Devlin, N., Bateman, A., Zamora, B. and Parkin, D., 2019. Distribution of the EQ-5D-5L Profiles and…
Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds
3 March 2020
…A., 2019. Exploring variations in the opportunity cost cost-effectiveness threshold by clinical area: Results from a feasibility study in England. OHE Research Paper 18/07. Available at https://www.ohe.org/publications/exploring-variations-opportunity-cost-cost-effectiveness-threshold-clinical-area Hernandez-Villafuerte, K., Zamora,…
How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.
26 March 2020
…payments for new antibiotics from the volumes used. The UK proposals by NICE and NHS England have the overall objective to put in place a subscription model for purchasing antibiotics…
The Digitalisation of Health Care During COVID-19: Consideration of the Long-Term Consequences
28 April 2020
…has been an increase in attention towards the potential of digital technologies in the health care space as they offer a means of addressing this problem: for example, in England…
OHE Awarded Independent Research Organisation (IRO) Status by UKRI
20 May 2020
…we have been awarded Independent Research Organisation (IRO) status. This has been granted by UK Research and Innovation (UKRI), which – through the seven Research Councils, Innovate UK and Research England –…
OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare
15 June 2020
…from a feasibility study in England. OHE Research Paper 18/07. Hernandez-Villafuerte, K., Zamora, B. and Towse, A., 2018. Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New…
Victor R. Fuchs Award for 2020 Goes to Patricia Danzon
23 June 2020
…University of Oxford, England, and a Ph.D. in Economics from the University of Chicago. She has also held faculty positions at Duke University and the University of Chicago. She is…
NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?
30 July 2020
…Health Service (NHS) in England based on their clinical and cost-effectiveness, through their Technology Appraisal (TA) programme. Following review, the main TA outcomes are to ‘recommend’ the medicine (in line…
Establishing a Reasonable Price for an Orphan Drug
11 September 2020
…SMC and NICE define ultra-orphan drugs as medicines granted orphan status by the EMA and treating conditions with a prevalence of 1 in 50,000 people in England and/or Scotland –…